Ipsen's Stock Surges 6.19% After Quarterly Results Exceed Expectations
The biopharmaceutical company's stock broke through its technical resistance level at 120 euros this Wednesday morning, driven by the publication of third-quarter results that exceeded expectations and the announcement of a strategic acquisition in immuno-oncology.
Significant Rise in Ipsen's Stock
Ipsen's stock showed a marked increase of 6.19% this morning, with the stock price reaching 120.10 € in the early hours of trading. This rise is part of a positive short-term dynamic, with the stock having gained 5.54% over the past seven days and 12.88% over the last three months. The publication of the third-quarter 2025 results this morning is the main catalyst for this movement. The biopharmaceutical group recorded a revenue of 915 million euros for the July-September period, surpassing the 894 million euros anticipated by analysts. For the first nine months of the year, total sales amounted to 2.73 billion euros, up 12.1% at constant exchange rates. This performance led the company to revise its annual forecasts upwards, now expecting sales growth of about 10% compared to more than 7% previously, while the operating margin is expected to be around 35% of revenue, up from more than 32% previously.
Strategic Acquisition Announced
Alongside this publication, Ipsen announced the signing of a definitive agreement for the acquisition of ImCheck Therapeutics, a French company specializing in immuno-oncology therapies. The transaction includes an initial payment of 350 million euros, supplemented by deferred payments that could bring the total amount up to 1 billion euros depending on the achievement of regulatory and commercial targets. Technically, the stock price this morning broke through its resistance level at 120.00 €, a signal generally interpreted as a potential for continuation of the upward movement in the short term. The stock is now clearly above its 50-day moving average, established at 115.68 €, confirming a favorable underlying trend. The share of capital traded remains moderate at 0.1%, reflecting limited trading volumes in the early moments of the session.
Technical Reversal Indicated
The Relative Strength Index (RSI) is positioned at 31, a level that traditionally indicates an oversold zone and suggests that the stock might have been neglected before this rebound. This positioning contrasts with the marked rise observed this morning, illustrating a significant technical turnaround. Moreover, with a negative beta of -0.16, Ipsen shows an inverse correlation with the movements of the CAC 40, which is down 0.69% at the same time. This characteristic gives the stock a defensive profile, sought after by investors in times of uncertainty. Over the past year, the stock's performance remains modest at +4.8%, slightly underperforming the Parisian index which has shown a progression of 8.83% over the same period.
